TY - JOUR T1 - Current state, control, impact and management of rheumatoid arthritis according to patient: AR 2020 national survey JO - Reumatología Clínica (English Edition) T2 - AU - Alcaide,Laly AU - Torralba,Antonio I. AU - Eusamio Serre,José AU - García Cotarelo,Carlos AU - Loza,Estíbaliz AU - Sivera,Francisca SN - 21735743 M3 - 10.1016/j.reumae.2021.03.002 DO - 10.1016/j.reumae.2021.03.002 UR - https://reumatologiaclinica.org/en-current-state-control-impact-management-articulo-S217357432100068X AB - ObjectivesTo analyse current status, control and impact of RA on patients’ lives as well as the management of RA symptoms. MethodsA structured anonymous online questionnaire was designed and sent to patients with RA, aged 18 years or above living in Spain. Participants were invited though different strategies: 1) ConArtritis and related patients associations; 2) Patients participating in the platform www.in-pacient.es; 3) Links from ConArtritis website and open social networks. Sociodemographic and clinical variables, as well as others related to the objectives were collected. A descriptive analysis was performed. ResultsWe analysed 882 RA patients, 89% women, with a median age of 52 years, 31.9% disease duration <5 years. They reported a mean pain and patient global disease score (0−10) of 5.1 and 4.9 respectively. The rate of patients with many difficulties or inability to perform daily tasks varied from 6.4% to 49.2%. Based on the activity index 56.8% of patients reported high activity. We found a great or severe impact on the emotional well-being in 31.5% of patients, and of 29.2% in the workplace or academic setting. A total of 87.9% are taking some medication for RA, and 17.3% are little/not satisfied with them. In addition, 67.1% take conventional synthetic disease modifying drugs (DMARDs), and 45.9% biological therapies including biosimilars and small molecules. ConclusionsThe current impact of RA on patients’ daily lives remains very high. A significant number of patients are not taking DMARDs (conventional synthetic and/or biologics) despite high activity. ER -